<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1405-9940</journal-id>
<journal-title><![CDATA[Archivos de cardiología de México]]></journal-title>
<abbrev-journal-title><![CDATA[Arch. Cardiol. Méx.]]></abbrev-journal-title>
<issn>1405-9940</issn>
<publisher>
<publisher-name><![CDATA[Instituto Nacional de Cardiología Ignacio Chávez]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1405-99402017000200124</article-id>
<article-id pub-id-type="doi">10.1016/j.acmx.2016.06.006</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Reunión multidisciplinaria sobre el uso de los anticoagulantes orales directos en la fibrilación auricular no valvular]]></article-title>
<article-title xml:lang="en"><![CDATA[Multidisciplinary meeting about the use of direct oral anticoagulants in nonvalvular atrial fibrillation]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rodríguez-Reyes]]></surname>
<given-names><![CDATA[Humberto]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Arauz-Góngora]]></surname>
<given-names><![CDATA[Antonio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Asensio-Lafuente]]></surname>
<given-names><![CDATA[Enrique]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Celaya-Cota]]></surname>
<given-names><![CDATA[Manuel de Jesús]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cordero-Cabra]]></surname>
<given-names><![CDATA[Alejandro]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Guevara-Valdivia]]></surname>
<given-names><![CDATA[Milton]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Izaguirre-Avila]]></surname>
<given-names><![CDATA[Raúl]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Lara-Vaca]]></surname>
<given-names><![CDATA[Susano]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Mariona-Moreno]]></surname>
<given-names><![CDATA[Vitelio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Martínez-Flores]]></surname>
<given-names><![CDATA[Enrique]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Nava-Townsend]]></surname>
<given-names><![CDATA[Santiago]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pozas-Garza]]></surname>
<given-names><![CDATA[Gerardo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rodríguez-Diez]]></surname>
<given-names><![CDATA[Gerardo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Sociedad Cardiovascular y Arritmias  ]]></institution>
<addr-line><![CDATA[Aguascalientes ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Instituto Nacional de Neurología y Neurocirugía  ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Hospital Médica TEC 100  ]]></institution>
<addr-line><![CDATA[Querétaro ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Instituto de Corazón CIMA  ]]></institution>
<addr-line><![CDATA[Hermosillo Sonora]]></addr-line>
<country>México</country>
</aff>
<aff id="Af5">
<institution><![CDATA[,Instituto Cardiovascular de Guadalajara  ]]></institution>
<addr-line><![CDATA[Guadalajara ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af6">
<institution><![CDATA[,Instituto Mexicano del Seguro Social Centro Médico Nacional La Raza ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af7">
<institution><![CDATA[,Instituto Nacional de Cardiología «Ignacio Chávez»  ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af8">
<institution><![CDATA[,IMSS Centro Médico ]]></institution>
<addr-line><![CDATA[León Guanajuato]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af9">
<institution><![CDATA[,IMSS Centro Médico Nacional de Occidente ]]></institution>
<addr-line><![CDATA[Guadalajara ]]></addr-line>
<country>México</country>
</aff>
<aff id="A10">
<institution><![CDATA[,Instituto Mexicano del Seguro Social Centro Médico Nacional Siglo XXI ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="A11">
<institution><![CDATA[,Instituto Nacional de Cardiología «Ignacio Chávez»  ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<aff id="A12">
<institution><![CDATA[,TEC de Monterrey  ]]></institution>
<addr-line><![CDATA[Monterrey ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="A13">
<institution><![CDATA[,Instituto Mexicano del Seguro Social Centro Médico Nacional 20 de Noviembre ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2017</year>
</pub-date>
<volume>87</volume>
<numero>2</numero>
<fpage>124</fpage>
<lpage>143</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S1405-99402017000200124&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S1405-99402017000200124&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S1405-99402017000200124&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen: Conociendo el impacto real de la fibrilación auricular en el evento vascular cerebral, la Sociedad Mexicana de Electrofisiología y Estimulación Cardiaca (SOMEEC) contempló la iniciativa de desarrollar una reunión multidisciplinaria de expertos con la finalidad de actualizar la evidencia científica disponible a partir de guías de práctica clínica, metaanálisis y ensayos clínicos controlados, y complementarla con la experiencia y los puntos de vista de un grupo de expertos. Para cumplir con este objetivo, se reunió a un grupo de especialistas en el área de cardiología, electrofisiología, neurología y hematología que, dada su experiencia en ciertas áreas, compartieron la evidencia científica disponible ante el panel de expertos para dejar abierta una discusión sobre la información que se presentaría en el presente artículo. Este documento reúne la mejor evidencia científica disponible y pretende ser una herramienta útil que agilice la toma de decisiones para uso de los nuevos anticoagulantes orales en fibrilación auricular no valvular y cardiopatía isquémica, o referente al manejo de pacientes que presentan evento vascular cerebral, o insuficiencia renal, e incluso en aquellos que serán sometidos a procedimientos invasivos y cirugía electiva. En la misma se manejan esquemas comparativos de seguimiento y tratamiento que simplifica la toma de decisión por los especialistas participantes.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract: Knowing the real impact of atrial fibrillation in the stroke, the Sociedad Mexicana of Electrofisiología y Estimulación Cardiaca (SOMEEC) had the initiative to develop a multidisciplinary meeting of experts the with the purpose to update the available scientific evidence from clinical practice guidelines, meta-analyses, controlled clinical trials, and complementing with the experience and views of a group of experts. To meet this goal, SOMEEC gathered a group of specialists in the area of cardiology, electrophysiology, neurology and hematology that given their experience in certain areas, they share the scientific evidence with the panel of experts to leave open a discussion about the information presented in this article. This document brings together the best scientific evidence available and aims to be a useful tool in the decision to use of new oral anticoagulants in nonvalvular atrial fibrillation and ischemic heart disease, or relating to the management of patients with stroke or renal failure, and even those that will be submitted to elective surgery and invasive procedures. In the same, they handled comparative schemes of follow-up and treatment which simplifies the decision making by the specialists participants.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Anticoagulantes orales]]></kwd>
<kwd lng="es"><![CDATA[Fibrilación auricular]]></kwd>
<kwd lng="es"><![CDATA[Sociedad Mexicana de Electrofisiología y Estimulación Cardiaca]]></kwd>
<kwd lng="es"><![CDATA[Apixabán]]></kwd>
<kwd lng="es"><![CDATA[Dabigatrán]]></kwd>
<kwd lng="es"><![CDATA[Rivaroxabán]]></kwd>
<kwd lng="es"><![CDATA[México]]></kwd>
<kwd lng="en"><![CDATA[Oral anticoagulants]]></kwd>
<kwd lng="en"><![CDATA[Atrial fibrillation]]></kwd>
<kwd lng="en"><![CDATA[Sociedad Mexicana de Electrofisiología y Estimulación Cardiaca]]></kwd>
<kwd lng="en"><![CDATA[Apixaban]]></kwd>
<kwd lng="en"><![CDATA[Dabigatran]]></kwd>
<kwd lng="en"><![CDATA[Rivaroxaban]]></kwd>
<kwd lng="en"><![CDATA[Mexico]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Guidelines Management of Atrial Fibrillation of the European Society of Cardiology. Guidelines for the management of atrial fibrillation]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Camm]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Kirchhof]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Lip]]></surname>
<given-names><![CDATA[GYH]]></given-names>
</name>
</person-group>
<source><![CDATA[Eur Heart J]]></source>
<year>2010</year>
<volume>31</volume>
<page-range>2369&#8211;429</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[January]]></surname>
<given-names><![CDATA[CT]]></given-names>
</name>
<name>
<surname><![CDATA[Wann]]></surname>
<given-names><![CDATA[LS]]></given-names>
</name>
<name>
<surname><![CDATA[Alpert]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
</person-group>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2014</year>
<volume>64</volume>
</nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Registro Mexicano de Fibrilación Auricular]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lara-Vaca]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Cordero-Cabra]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez-Flores]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<source><![CDATA[Gaceta Méd México]]></source>
<year>2014</year>
<volume>150</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>48&#8211;59</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Impact of double-blind vs. open study design on the observed treatment effects of new oral anticoagulants in atrial fibrillation: A meta-analysis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lega]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Mismetti]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Cucherat]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[J Thromb Haemost]]></source>
<year>2013</year>
<volume>11</volume>
<page-range>1240&#8211;50</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Nuevos anticoagulantes orales y su papel en la práctica clínica]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mateo]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Rev Esp Cardiol Supl]]></source>
<year>2013</year>
<volume>13</volume>
<page-range>33&#8211;41</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomised trials]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ruff]]></surname>
<given-names><![CDATA[CT]]></given-names>
</name>
<name>
<surname><![CDATA[Giugliano]]></surname>
<given-names><![CDATA[RP]]></given-names>
</name>
<name>
<surname><![CDATA[Braunwald]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<source><![CDATA[Lancet]]></source>
<year>2014</year>
<volume>383</volume>
<page-range>955&#8211;62</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Clinical strategies for selecting oral anticoagulants in patients with atrial fibrillation]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pokorney]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Sherwood]]></surname>
<given-names><![CDATA[MW]]></given-names>
</name>
<name>
<surname><![CDATA[Becker]]></surname>
<given-names><![CDATA[RC]]></given-names>
</name>
</person-group>
<source><![CDATA[J Thromb Thrombolysis]]></source>
<year>2013</year>
<volume>36</volume>
<page-range>163</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Dabigatran, rivaroxaban, or apixaban versus warfarin in patients with nonvalvular atrial fibrillation: A systematic review and meta-analysis of subgroups]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gómez-Outes]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Terleira-Fernández]]></surname>
<given-names><![CDATA[AI]]></given-names>
</name>
<name>
<surname><![CDATA[Calvo-Rojas]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<source><![CDATA[Thrombosis]]></source>
<year>2013</year>
<volume>2013</volume>
<page-range>640&#8211;723</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Apixaban versus warfarin in patients with atrial fibrillation]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Granger]]></surname>
<given-names><![CDATA[CB]]></given-names>
</name>
<name>
<surname><![CDATA[Alexander]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[McMurray]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
</person-group>
<source><![CDATA[N Engl J Med]]></source>
<year>2011</year>
<volume>365</volume>
<page-range>981&#8211;92</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ageno]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Gallus]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Wittkowsky]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Chest]]></source>
<year>2012</year>
<volume>141</volume>
<numero>^s2</numero>
<issue>^s2</issue>
<supplement>2</supplement>
<page-range>e44S-88S</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[New oral anticoagulants vs vitamin K antagonists: Benefits for health-related quality of life in patients with atrial fibrillation]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alegret]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Viñolas]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Arias]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<source><![CDATA[Int J Med Sci]]></source>
<year>2014</year>
<volume>11</volume>
<page-range>680&#8211;4</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Novel anticoagulants for stroke prevention in atrial fibrillation: Current clinical evidence and future developments]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schirmer]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
<name>
<surname><![CDATA[Baumhäkel]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Neuberger]]></surname>
<given-names><![CDATA[HR]]></given-names>
</name>
</person-group>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2010</year>
<volume>56</volume>
<page-range>2067&#8211;76</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Clinical trials with new oral anticoagulants. Additive value of indirect comparisons also named network meta-analyses]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Harenberg]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Weiss]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<source><![CDATA[Hamostaseologie]]></source>
<year>2013</year>
<volume>33</volume>
<page-range>62&#8211;70</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[A new era of stroke prevention in atrial fibrillation: Comparing a new generation of oral anticoagulants with warfarin]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stambler]]></surname>
<given-names><![CDATA[BS]]></given-names>
</name>
</person-group>
<source><![CDATA[Int Arch Med]]></source>
<year>2013</year>
<volume>6</volume>
<page-range>46</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[New oral anticoagulants: Are coagulation units still required?]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Altman]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[Thromb J]]></source>
<year>2014</year>
<volume>12</volume>
<page-range>3</page-range></nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Selecting antithrombotic therapy for patients with atrial fibrillation]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tanaka-Esposito]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Chung]]></surname>
<given-names><![CDATA[MK]]></given-names>
</name>
</person-group>
<source><![CDATA[Cleve Clin J Med]]></source>
<year>2015</year>
<volume>82</volume>
<page-range>49&#8211;63</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[New oral anticoagulant drugs in cardiovascular disease]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ahrens]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Lip]]></surname>
<given-names><![CDATA[GY]]></given-names>
</name>
<name>
<surname><![CDATA[Peter]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<source><![CDATA[Thromb Haemost]]></source>
<year>2010</year>
<volume>104</volume>
<page-range>49&#8211;60</page-range></nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Dabigatran versus warfarin in patients with atrial fibrillation]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Connolly]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Ezekowitz]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[Yusuf]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[N Engl J Med]]></source>
<year>2009</year>
<volume>361</volume>
<page-range>1139&#8211;51</page-range></nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Dabigatran: An alternative to warfarin]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Blacksmith]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<source><![CDATA[Cleveland Clinic]]></source>
<year>2011</year>
<volume>14</volume>
<page-range>1&#8211;5</page-range></nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Update on the status of new oral anticoagulants for stroke prevention in patients with atrial fibrillation update on the status of new oral anticoagulants for stroke prevention in patients with atrial fibrillation]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Holy]]></surname>
<given-names><![CDATA[WE]]></given-names>
</name>
<name>
<surname><![CDATA[Beer]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Cardiovascular Medicine]]></source>
<year>2013</year>
<volume>16</volume>
<page-range>103&#8211;14</page-range></nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The newer direct oral anticoagulants: A practical guide]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thachil]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin Med]]></source>
<year>2014</year>
<volume>14</volume>
<page-range>165&#8211;75</page-range></nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The efficacy and safety of oral anticoagulants in warfarin-suitable patients with nonvalvular atrial fibrillation: Systematic review and meta-analysis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mitchell]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Simon]]></surname>
<given-names><![CDATA[TA]]></given-names>
</name>
<name>
<surname><![CDATA[Raza]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin Appl Thromb Hemost]]></source>
<year>2013</year>
<volume>19</volume>
<page-range>619&#8211;31</page-range></nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Heidbuchel]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Verhamme]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Alings]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Europace]]></source>
<year>2013</year>
<volume>15</volume>
<page-range>625&#8211;51</page-range></nlm-citation>
</ref>
<ref id="B24">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Treatment discontinuations with new oral agents for long-term anticoagulation: Insights from a meta-analysis of 18 randomized trials including 101,801 patients]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chatterjee]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Sardar]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Giri]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
</person-group>
<source><![CDATA[May Clin Proc]]></source>
<year>2014</year>
<volume>89</volume>
<page-range>896&#8211;907</page-range></nlm-citation>
</ref>
<ref id="B25">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[An updated review of target-specific oral anticoagulants used in stroke prevention in atrial fibrillation, venous thromboembolic disease, and acute coronary syndromes]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cove]]></surname>
<given-names><![CDATA[CL]]></given-names>
</name>
<name>
<surname><![CDATA[Hylek]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
</person-group>
<source><![CDATA[J Am Heart Assoc]]></source>
<year>2013</year>
<volume>2</volume>
<page-range>e000136</page-range></nlm-citation>
</ref>
<ref id="B26">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[You]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Singer]]></surname>
<given-names><![CDATA[DE]]></given-names>
</name>
<name>
<surname><![CDATA[Howard]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
</person-group>
<source><![CDATA[Chest]]></source>
<year>2012</year>
<volume>141</volume>
<numero>^s2</numero>
<issue>^s2</issue>
<supplement>2</supplement>
<page-range>e531S-75S</page-range></nlm-citation>
</ref>
<ref id="B27">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lip]]></surname>
<given-names><![CDATA[GY]]></given-names>
</name>
<name>
<surname><![CDATA[Andreotti]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Fauchier]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<source><![CDATA[Europace]]></source>
<year>2011</year>
<volume>13</volume>
<page-range>723&#8211;46</page-range></nlm-citation>
</ref>
<ref id="B28">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Management of acute stroke in patients taking novel oral anticoagulants]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hankey]]></surname>
<given-names><![CDATA[GJ]]></given-names>
</name>
<name>
<surname><![CDATA[Norrving]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Hacke]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<source><![CDATA[Int J Stroke]]></source>
<year>2014</year>
<volume>9</volume>
<page-range>627&#8211;32</page-range></nlm-citation>
</ref>
<ref id="B29">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Clinical review: Clinical management of new oral anticoagulants: A structured review with emphasis on the reversal of bleeding complications]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lazo-Langner]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lang]]></surname>
<given-names><![CDATA[ES]]></given-names>
</name>
<name>
<surname><![CDATA[Douketis]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Crit Care]]></source>
<year>2013</year>
<volume>17</volume>
<page-range>230</page-range></nlm-citation>
</ref>
<ref id="B30">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[How I treat target-specific oral anticoagulant-associated bleeding]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Siegal]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Garcia]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Crowther]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<source><![CDATA[Blood]]></source>
<year>2014</year>
<volume>123</volume>
<page-range>1152&#8211;8</page-range></nlm-citation>
</ref>
<ref id="B31">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Guidelines for the early management of patients with acute ischemic stroke: A guideline for healthcare professionals from the American Heart Association/American stroke Association]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jauch]]></surname>
<given-names><![CDATA[EC]]></given-names>
</name>
<name>
<surname><![CDATA[Saber]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Adams Jr]]></surname>
<given-names><![CDATA[HP]]></given-names>
</name>
</person-group>
<source><![CDATA[Stroke]]></source>
<year>2013</year>
<volume>44</volume>
<page-range>870&#8211;947</page-range></nlm-citation>
</ref>
<ref id="B32">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Use of new-generation oral anticoagulant agents in patients receiving antiplatelet therapy after an acute coronary syndrome: Systematic review and meta-analysis of randomized controlled trials]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Komócsi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Vorobcsuk]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kehl]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<source><![CDATA[Arch Intern Med]]></source>
<year>2012</year>
<volume>172</volume>
<page-range>1537&#8211;45</page-range></nlm-citation>
</ref>
<ref id="B33">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Novel oral anticoagulants in acute coronary syndrome: Re-evaluating the thrombin hypothesis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bassand]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
</person-group>
<source><![CDATA[EuroIntervention]]></source>
<year>2014</year>
<volume>9</volume>
<page-range>1333&#8211;41</page-range></nlm-citation>
</ref>
<ref id="B34">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Novel oral anticoagulants in acute coronary syndrome]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Costopoulos]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Niespialowska-Steuden]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kukreja]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<source><![CDATA[Int J Cardiol]]></source>
<year>2013</year>
<volume>167</volume>
<page-range>2449&#8211;55</page-range></nlm-citation>
</ref>
<ref id="B35">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Is there a role for novel oral anticoagulants in patients with an acute coronary syndrome? A review of the clinical trials]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liew]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Darvish-Kazem]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Douketis]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
</person-group>
<source><![CDATA[Pol Arch Med Wewn]]></source>
<year>2013</year>
<volume>123</volume>
<page-range>617&#8211;22</page-range></nlm-citation>
</ref>
<ref id="B36">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Efficacy and safety of direct oral anticoagulants in patients undergoing cardioversion for atrial fibrillation: A systematic review and meta-analysis of the literature]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dentali]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Botto]]></surname>
<given-names><![CDATA[GL]]></given-names>
</name>
<name>
<surname><![CDATA[Gianni]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Int J Cardiol]]></source>
<year>2015</year>
<volume>185</volume>
<page-range>72&#8211;7</page-range></nlm-citation>
</ref>
<ref id="B37">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Safety of short-term use of dabigatran or rivaroxaban for direct-current cardioversion in patients with atrial fibrillation and atrial flutter]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yadlapati]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Groh]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Passman]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Cardiol]]></source>
<year>2014</year>
<volume>113</volume>
<page-range>1362&#8211;3</page-range></nlm-citation>
</ref>
<ref id="B38">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Dabigatran versus warfarin in patients with atrial fibrillation: An analysis of patients undergoing cardioversion]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nagarakanti]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Ezekowitz]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[Oldgren]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Circulation]]></source>
<year>2011</year>
<volume>123</volume>
<page-range>131&#8211;6</page-range></nlm-citation>
</ref>
<ref id="B39">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation)]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Flaker]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Lopes]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
<name>
<surname><![CDATA[Al-Khatib]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
</person-group>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2014</year>
<volume>63</volume>
<page-range>1082&#8211;7</page-range></nlm-citation>
</ref>
<ref id="B40">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Piccini]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Stevens]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Lokhnygina]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2013</year>
<volume>61</volume>
<page-range>1998&#8211;2006</page-range></nlm-citation>
</ref>
<ref id="B41">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cappato]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Ezekowitz]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[Klein]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
</person-group>
<source><![CDATA[Eur Heart J]]></source>
<year>2014</year>
<volume>35</volume>
<page-range>3346&#8211;55</page-range></nlm-citation>
</ref>
<ref id="B42">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Novel oral anticoagulants for stroke prevention in atrial fibrillation: A focus on the older patient]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yates]]></surname>
<given-names><![CDATA[SW]]></given-names>
</name>
</person-group>
<source><![CDATA[Int J Gen Med]]></source>
<year>2013</year>
<volume>6</volume>
<page-range>167&#8211;80</page-range></nlm-citation>
</ref>
<ref id="B43">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Concerns about the use of new oral anticoagulants for stroke prevention in elderly patients with atrial fibrillation]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stöllberger]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Finsterer]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Drugs Aging]]></source>
<year>2013</year>
<volume>30</volume>
<page-range>949&#8211;58</page-range></nlm-citation>
</ref>
<ref id="B44">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Anticoagulation in patients aged &#8805; 75 years with atrial fibrillation: Role of novel oral anticoagulants]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ng]]></surname>
<given-names><![CDATA[KH]]></given-names>
</name>
<name>
<surname><![CDATA[Hart]]></surname>
<given-names><![CDATA[RG]]></given-names>
</name>
<name>
<surname><![CDATA[Eikelboom]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
</person-group>
<source><![CDATA[Cardiol Ther]]></source>
<year>2013</year>
<volume>2</volume>
<page-range>135&#8211;49</page-range></nlm-citation>
</ref>
<ref id="B45">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Updates in the perioperative and emergency management of non-vitamin K antagonist oral anticoagulants]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Faraoni]]></surname>
</name>
<name>
<surname><![CDATA[Levy]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Albaladejo]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<source><![CDATA[Crit Care]]></source>
<year>2015</year>
<volume>19</volume>
<page-range>203</page-range></nlm-citation>
</ref>
<ref id="B46">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Perioperative management of patients on new oral anticoagulants]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lai]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Davidson]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Galloway]]></surname>
<given-names><![CDATA[SW]]></given-names>
</name>
</person-group>
<source><![CDATA[Br J Surg]]></source>
<year>2014</year>
<volume>101</volume>
<page-range>742&#8211;9</page-range></nlm-citation>
</ref>
<ref id="B47">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Perioperative management issues of direct oral anticoagulants]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kozek-Langenecker]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
</person-group>
<source><![CDATA[Semin Hematol]]></source>
<year>2014</year>
<volume>51</volume>
<page-range>112&#8211;20</page-range></nlm-citation>
</ref>
<ref id="B48">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Medical costs of oral anticoagulants vs warfarin for atrial fibrillation patients with different stroke risks]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Deitelzweig]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Amin]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Jing]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<source><![CDATA[Cardiol Ther]]></source>
<year>2013</year>
<volume>2</volume>
<page-range>165&#8211;70</page-range></nlm-citation>
</ref>
<ref id="B49">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Análisis coste-efectividad de dabigatrán para la prevención de ictus y embolia sistémica en fibrilación auricular no valvular en España]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[González-Juanatey]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Álvarez-Sabin]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Lobos]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<source><![CDATA[Rev Esp Cardiol]]></source>
<year>2012</year>
<volume>65</volume>
<page-range>901&#8211;10</page-range></nlm-citation>
</ref>
<ref id="B50">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Economic evaluation of warfarin, dabigatran, rivaroxaban, and apixaban for stroke prevention in atrial fibrillation]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wisløff]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Hagen]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Klemp]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Pharmacoeconomics]]></source>
<year>2014</year>
<volume>32</volume>
<page-range>601&#8211;12</page-range></nlm-citation>
</ref>
<ref id="B51">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Anticoagulation for atrial fibrillation: Is this the end of warfarin? Not just yet]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mallouppas]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Vassiliou]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<source><![CDATA[Journal of Angiology]]></source>
<year>2013</year>
<volume>2013</volume>
<page-range>7</page-range></nlm-citation>
</ref>
<ref id="B52">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Left atrial appendage closure: A new technique for clinical practice]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Camm]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Colombo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Corbucci]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<source><![CDATA[Heart Rhythm]]></source>
<year>2014</year>
<volume>11</volume>
<page-range>514&#8211;21</page-range></nlm-citation>
</ref>
<ref id="B53">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[ACC/HRS/SCAI left atrial appendage occlusion device societal overview]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Masoudi]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Calkins]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Kavinsky]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<source><![CDATA[Heart Rhythm]]></source>
<year>2015</year>
<volume>12</volume>
</nlm-citation>
</ref>
<ref id="B54">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation. 2.3-year follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation) trial]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Reddy]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Doshi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Sievert]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<source><![CDATA[Circulation]]></source>
<year>2013</year>
<volume>127</volume>
<page-range>720&#8211;9</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
